Memorial Sloan Kettering Cancer Center
ASCO® GI 2024 Insights: "PROOF 301 Trial - Oral FGFR Inhibitor Infigratinib vs. Gemcitabine + Cisplatin in Patients With Advanced Cholangiocarcinoma With an FGFR2 Gene Fusion/Rearrangement"
Login to view comments.
Click here to Login